2025 Annual Shareholders' Meeting Results

News Release STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) 2025 Annual Shareholders’ Meeting Results Auckland, New Zealand, 21 August 2025 – Fisher & Paykel Healthcare Corporation Limited advises that all resolutions put to the company’s annual shareholders’ meeting held today were passed. The seven resolutions were: Resolution 1: To re-elect Neville Mitchell as a Director. Resolution 2: To re-elect Lewis Gradon as a Director. Resolution 3: To re-elect Lisa McIntyre as a Director. Resolution 4: To re-elect Cather Simpson as a Director. Resolution 5: To elect Mark Cross as a Director. Resolution 6: To authorise the Directors to fix the fees and expenses of the company’s auditor. Resolution 7: To approve the grant of discretionary long term variable remuneration instruments to Lewis Gradon as set out in the Notice of Annual Shareholders’ Meeting 2025. All resolutions were decided by poll. The details of the total number of votes cast online, in person or by proxy on the polls were as follows: Resolution Votes: Resolution 1: Re-election of Neville Mitchell as a Director. For: 429,216,814 (97.36%); Against: 11,652,978 (2.64%); Abstain: 1,299,617 Resolution 2: Re-election of Lewis Gradon as a Director. For: 441,426,824 (99.97%); Against: 139,173 (0.03%); Abstain: 601,896 Resolution 3: Re-election of Lisa McIntyre as a Director. For: 430,486,886 (97.37%); Against: 11,642,888 (2.63%); Abstain: 39,635 Resolution 4: Re-election of Cather Simpson as a Director. For: 441,889,235 (99.95%); Against: 243,087 (0.05%); Abstain: 37,087 Resolution 5: Election of Mark Cross For: 437,480,939 (98.98%); Against: 4,489,818 (1.02%); Abstain: 198,652 Resolution 6: Approval of auditors' fees and expenses For: 437,099,574 (99.05%); Against: 4,211,623 (0.95%); Abstain: 858,212 Resolution 7: Grant of discretionary long term variable remuneration instruments to Lewis Gradon For: 431,000,052 (97.82%); Against: 9,625,215 (2.18%); Abstain: 963,529 About Fisher & Paykel Healthcare Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com. Contacts Media Karen Knott GM Corporate Communications karen.knott@fphcare.co.nz +64 (0) 21 713 911 Investors Dan Adolph Head of Investor Relations daniel.adolph@fphcare.co.nz +64 (0) 22 511 4050 Authorised by Raelene Leonard, General Counsel & Company Secretary.